Lexeo Therapeutics, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 3 insiders sold shares within a monthSince Aug 18, 2026+4
Trials
- LXEOLexeo Therapeutics4Calm
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
Signing up patientsPhase 226 patientsMain results: Jun 2032 - LXEOLexeo Therapeutics4Calm
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Running, no new patientsPhase 1/28 patientsMain results: Sep 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
9 sales (9 not pre-planned) · 0 purchases
- Tamayo Louis EdwardChief Financial Officer · Aug 18, 2026Sold 4,117 sharesabout $20 thousand · not pre-planned
- Townsend Richard NolanChief Executive Officer · Aug 18, 2026Sold 3,345 sharesabout $17 thousand · not pre-planned
- Otero Jose ManuelChief Operating Officer · Aug 18, 2026Sold 1,304 sharesabout $6 thousand · not pre-planned
- Tamayo Louis EdwardChief Financial Officer · Jul 1, 2026Sold 4,641 sharesabout $21 thousand · not pre-planned
- Otero Jose ManuelChief Operating Officer · Jul 1, 2026Sold 4,666 sharesabout $21 thousand · not pre-planned
- Bhalla Narinder Pal
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.